Research Article

Serological and virological profile of patients with chronic hepatitis B infection in Eritrea

Mohammed Elfatih Hamida*, Saud Mohammed Raja, Yemane Seyoum, Isam Mohammed Elkhidir and Freweini Tekle

Published: 24 July, 2020 | Volume 4 - Issue 1 | Pages: 096-101

Background: Hepatitis B virus infection is a major cause of liver associated morbidity and mortality with diverse spectrum of disease. It is estimated about 15% to 40% of patients with hepatitis B virus infection progress to chronic hepatitis and about 15% to 25% die from disease complications. The main aim of this study was to evaluate the serological and virological markers of patients with chronic hepatitis B virus infection to determine the natural history of chronic hepatitis B infection in the Eritrean setting.

Methods: A laboratory-based cross-sectional study was conducted on 305 patients with HBsAg positive who presented to Orotta National Referral Hospital, Halibet Hospital, Sembel Hospital and National Health Laboratory in Asmara, Eritrea from January 2017 to February 2019. Enzyme-linked immunosorbent assay was performed to detect hepatitis B serological markers (anti-HBc, HBsAg, anti-HBsAb, HBeAg and anti-HBeAg). Hepatitis B DNA viral loads and liver transaminase levels were determined. Data analysis was conducted using SPSS version 25.0.

Results: A total of 305 patients presented with HBsAg positive serology with a mean age of 41.3 (± 13.7) years ranging from 16 to 78 years. Males were 218 (71.5%) and females 87 (28. 5%).Anti-HBc was positive in 300 (98.4%), of which 293 (97.5%) were positive for HBsAg and 7 (2.3%) positive for anti-HBs. Among these 293 patients, 20 (6.8%) were HBeAg positive/anti-HBe positive, 242 (82.6%) HBeAg-negative/anti-HBe-positive and 31 (10.6%) were HBeAg negative/anti-HBe-positive. Detectable HBV DNA was found in 122(41.6%) of the 293 cases. Alanine transaminase was normal in 90% of HBeAg-positive and in 91.2% of HBeAg-negative patients. Hepatitis B DNA viral load was >2,000 IU/mL in 67 (22.86%) and >200,000 IU/mL level was more frequently detected in HBeAg positive (20.0%) compared to HBeAg negative (1.8%) subjects (p < 0.001).

Conclusion: This study shows predominance of HBeAg-negative and low replication phase of HBV infection among patients in Eritrea. It also documented that most patients had chronic infection with normal liver transaminase levels in the absence of biochemical signs of hepatitis. This study will provide a basis for therapeutic evaluation of patients and planning national treatment guidelines in the Eritrean setting.

Read Full Article HTML DOI: 10.29328/journal.ijcv.1001022 Cite this Article Read Full Article PDF


Hepatitis B virus (HBV); Chronic Hepatitis B (CHB); Natural history; HBV DNA viral load; Low replicative phase; ELISA; PCR


  1. Global hepatitis report 2017. 2017: World Health Organization.
  2. Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res. 2007. 37: S9-S19. PubMed: https://pubmed.ncbi.nlm.nih.gov/17627641
  3. Bogler Y, Wong RJ, Gish RG. Epidemiology and Natural History of Chronic Hepatitis B Virus Infection, in Hepatitis B Virus and Liver Disease. Springer. 2018; 63-89.
  4. Lavanchy D, Kane M. Global epidemiology of hepatitis B virus infection, in Hepatitis B virus in human diseases. Springer. 2016; 187-203. PubMed:
  5. Yang HC, Shih YF, Liu CJ. Viral factors affecting the clinical outcomes of chronic hepatitis B. J Infect Dis. 2017; 216(suppl_8): S757-S764. PubMed:
  6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-185. PubMed: https://pubmed.ncbi.nlm.nih.gov/22436845/
  7. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, et al. A ASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63: 261-283. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987259/
  8. Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol. WJG. 2014; 20: 10395. PubMed: https://pubmed.ncbi.nlm.nih.gov/25132755/
  9. Lau GK. How do we handle the anti‐HBc positive patient? (in highly endemic settings). Clin Liver Dis. 2015; 5: 29-31. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490450/
  10. Liu J, Yang H, Lee M, Lu S, Jen C, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut. 2014; 63: 1648-1657. PubMed: https://pubmed.ncbi.nlm.nih.gov/24225939
  11. Kirk GD, Lesi OA, Mendy M, Akano AO, Sam O, et al. The Gambia Liver Cancer Study: Infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology. 2004; 39: 211-219. PubMed: https://pubmed.ncbi.nlm.nih.gov/14752840
  12. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar-15. 2015: World Health Organization.
  13. Li Q, Ren X, Lu C, Li W, Huang Y, et al, Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT≤ 2 ULN: A retrospective cohort study. Medicine. 2017; 96: e6336. PubMed: https://pubmed.ncbi.nlm.nih.gov/28328813/
  14. Fessehaye ND, Berhane NA, Ahimed H. Prevalence of hepatitis B virus infection and associated seromarkers among pregnant women in Eritrea. J Human Virol Retrovirol. 2018; 6: 00191.
  15. Fessehaye N, Naik D, Fessehaye T. Transfusion transmitted infections–A retrospective analysis from the National Blood Transfusion Service in Eritrea. Pan African Med J. 2011; 9; 40. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22145069
  16. Papatheodoridis GV, Manolakopoulos S, Liaw Y, Lok A. Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012; 57: 196-202. PubMed: https://pubmed.ncbi.nlm.nih.gov/22450396/
  17. Merican I. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000. 15: 1356-1361.
  18. Lesi O. Serological and virological markers of nigerian patients with hepatitis B infection. Niger J Clini Practice, 2019; 22: 534.
  19. Baig S. Gender disparity in infections of Hepatitis B virus. J Coll Physicians Surg Pak, 2009. 19: 598-600. PubMed: https://pubmed.ncbi.nlm.nih.gov/19728952/
  20. Souza ND. Assessment of health-related quality of life and related factors in patients with chronic liver disease. Bra J Infect Dis. 2015. 19: 590-595.
  21. Abdelmenan S, Banes A, Berhane Y, Abebe M, Wandall JH. Etiology of Chronic Liver Disease in Ethiopia: A Case Control Study with Special Reference to Viral Hepatitis and Alcohol. EC Gastroenterol Digestive Sys. 2018; 5: 120-128. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402780/
  22. Elmukashfi TA, Ibrahim OA, Elkhidir IM, Bashir AA, Elkarim MAA. Socio-demographic characteristics of health care workers and hepatitis B virus (HBV) infection in public teaching hospitals in Khartoum State, Sudan. Glob J Health Sci. 2012; 4: 37-41. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776931/
  23. Hoofnagle J, Gerety R, Barker L. Antibody to hepatitis-B-virus core in man. The Lancet. 1973; 302: 869-873.
  24. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008; 48: 1001-1026. PubMed: https://pubmed.ncbi.nlm.nih.gov/18454738/
  25. Liang X. Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination. Vaccine. 2013; 31: J21-J28. PubMed:
  26. Di Bisceglie AM, Lombardero M, Teckman J, Roberts L, Janssen HLA, et al, Determination of hepatitis B phenotype using biochemical and serological markers. J Viral Hepatitis. 2017; 24: 320-329. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27917600
  27. Terrault N. American Association for the Study of Liver D. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63: 261-283.
  28. Roos R. A cross sectional study of HBeAg negative chronic hepatitis B virus infection in Cape Town, South Africa: P067. J Viral Hepatitis. 2015; 22: 53-54.
  29. Ivón CFM, Zaily DG, Leda Patricia DCE, Enrique GG, Enrique AS, et al, Current Condition of Chronic Hepatitis B Virus Infection in Cuban Adults. Curr Ther Res Clin Exp. 2017; 85: 15-19. PubMed: https://pubmed.ncbi.nlm.nih.gov/29158854/
  30. Tufon KA, Anong DN, Meriki HD, Georges, TD, Maurice, M, et al, Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon. PloS one. 2018; 13: e0203312. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124766/
  31. Hadziyannis SJ, VassilopoulosD. Hepatitis B e antigen–negative chronic hepatitis B. Hepatology. 2001; 34: 617-624. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11584355
  32. Iregbu K, Nwajiobi‑Princewill PI. Viral Load Pattern Among Hepatitis B Surface Antigen‑positive Patients: Laboratory Perspective and Implications for Therapy. Ann Med Health Sci Res. 2016; 6: 95-99. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866374/


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?